MedTrace Logo

COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

NCT05772832 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2025-08-27

No results posted yet for this study

Summary

In patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist "Dexmedetomidine" and the rapid and short-acting opioid "Remifentanil" using the "Numerical Rating Scale" (NRS) administered alongside propofol in perioperative maintenance anesthesia. .

Conditions

  • Postoperative Pain

Interventions

DRUG

Dexmedetomidine

Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery

DRUG

Remifentanyl

Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery

Sponsors & Collaborators

  • Kocaeli University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2022-12-14
Completion
2023-02-22
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772832 on ClinicalTrials.gov